STOCK TITAN

Logicbio Therapeutics SEC Filings

LOGC OTC Link

Welcome to our dedicated page for Logicbio Therapeutics SEC filings (Ticker: LOGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The ContextLogic Holdings Inc. (LOGC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain complex documents. ContextLogic files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that describe its transformation into a business ownership platform, its financial condition and its material agreements.

For investors analyzing LOGC, the company’s 8-K filings are especially important. These include detailed descriptions of the purchase agreement to acquire US Salt Parent Holdings, LLC and its subsidiaries, outlining the transaction structure, consideration, pre-closing reorganizations and conditions to closing. Other 8-Ks cover the completion of the corporate reorganization that made ContextLogic Inc. a wholly owned subsidiary of ContextLogic Holdings Inc., the voluntary delisting from The Nasdaq Global Market and transition to the OTCQB Venture Market, and leadership changes such as executive appointments and resignations.

ContextLogic’s periodic reports discuss its lack of operating revenues after the sale of substantially all assets, its history of losses, its cash, cash equivalents and marketable securities, and risks related to future acquisitions, use of net operating loss carryforwards and potential investment company status. These filings also describe strategic investments from BC Partners in a subsidiary and options for additional capital in connection with future acquisitions.

On Stock Titan, users can review LOGC 10-K and 10-Q filings with AI-generated highlights that surface key sections on liquidity, risk factors, tax attributes and segment information. Current Reports on Form 8-K, including those related to the US Salt acquisition and governance changes, are summarized so readers can quickly understand the nature of each material event. Insider transaction reports on Form 4, when filed, can also be accessed to see equity activity by directors and officers. Real-time updates from EDGAR ensure that new filings appear promptly, while AI summaries help investors navigate lengthy documents and focus on the disclosures most relevant to ContextLogic’s evolving business model.

Rhea-AI Summary

ContextLogic Holdings Inc. furnished a Form 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The release is included as Exhibit 99.1.

The disclosure is provided under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), and is expressly stated as furnished, not filed under the Exchange Act.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
current report

FAQ

What is the current stock price of Logicbio Therapeutics (LOGC)?

The current stock price of Logicbio Therapeutics (LOGC) is $8.4804 as of March 17, 2026.

What is the market cap of Logicbio Therapeutics (LOGC)?

The market cap of Logicbio Therapeutics (LOGC) is approximately 216.4M.

LOGC Rankings

LOGC Stock Data

216.39M
27.73M
Internet Retail
Retail-catalog & Mail-order Houses
Link
United States
OAKLAND

LOGC RSS Feed